Cantor Fitzgerald analyst Charles Duncan upgrades Fennec Pharmaceuticals (NASDAQ:FENC) from Neutral to Overweight and raises the price target from $9 to $12.
Cowen & Co. analyst Charles Ryhee upgrades Walgreens Boots Alliance (NASDAQ:WBA) from Market Perform to Outperform and raises the price target from $43 to $54.